Top Markets
Coin of the day
Apimeds Pharmaceuticals US, Inc Apimeds Pharmaceuticals US, Inc

Apimeds Pharmaceuticals US, Inc

APUS
Rank in Stocks #33690
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage... Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.
Share Price
$4.70
Last synced: 2026-08-14
Market Cap
$7.09M
Change (1 day)
-0.21%
Change (1 year)
-70.63%
Country
US
Trade Apimeds Pharmaceuticals US, Inc (APUS)

Category

Operating Margin for Apimeds Pharmaceuticals US, Inc (APUS)
Operating Margin as of 2026 TTM: 0.00%
According to Apimeds Pharmaceuticals US, Inc latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Apimeds Pharmaceuticals US, Inc from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.